Introduction {#Sec1}
============

Long-term neurological conditions (LTNCs), including multiple sclerosis (MS), idiopathic Parkinson's disease (IPD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and motor neurone disease (MND), are non-communicable, progressive diseases that can affect patients' physical capability, sensory function, cognition, behaviour, communication and emotions^[@CR1]^.

Research has previously underestimated the burden of LTNCs by considering only mortality and not disability related outcomes^[@CR2]^, thus further research into the symptom experience of LTNC patients is warranted. Symptoms in LTNCs are common, multiple and insufficiently studied in the more advanced stages of disease, yet such information is vital to improve care^[@CR3]--[@CR5]^.

Investigating patient symptomatology requires the use of a valid measurement tool. Exploring a measure's psychometric properties often includes identifying the tool's internal consistency (a measure of scale reliability) and any floor and ceiling effects (where respondents excessively score at the lowest or highest end of the scale, respectively). The psychometric development of a validated tool may also include factor analysis, a statistical approach to identifying the internal structure of a measure by exploring the relatedness of individual items.

Factor analysis has been used previously to assess symptom profiles for cancer^[@CR6],[@CR7]^, heart failure, kidney disease^[@CR8]^ and acute mania^[@CR9]^. Assessing the factor structure of symptoms may contribute to the development of evidence-based diagnostic tools^[@CR9]^. This could benefit both health professionals and patients, as care can be focused on managing groups of symptoms, rather than inefficiently treating single symptoms^[@CR10]^.

A previous factor analysis of eight symptoms in LTNC patients^[@CR11]^ aimed to validate a shortened palliative care outcome measure for this patient group, but did not explore the factor structure of the whole spectrum of symptoms and identify clinically meaningful symptom clusters. No other studies have explored the factor structure of symptoms across LTNCs.

The present study aimed to explore the factor structure of a 24 item measure of symptoms in LTNC patients. It was hypothesised that, including a wider variety of symptoms, a factor analysis would identify a multi-factorial internal structure, which would illustrate distinct symptom dimensions across LTNCs.

Methods {#Sec2}
=======

Sample {#Sec3}
------

Patients were recruited for a trial investigating the effectiveness of a palliative care intervention from seven sites across the United Kingdom between April 2015 and August 2017 (the OPTCARE Neuro trial, NIHR trial registration number: ISRCTN18337380). Eligibility criteria were that patients had a diagnosis of either MS, Parkinsonism or related disorders (including IPD, PSP and MSA), or MND. Patients were also required not to have received specialist palliative care in the last six months, to have an unresolved symptom not responding to usual care and have at least one of the following: another unresolved symptom, cognitive problems or complex psychological/social needs. Patients were referred to the study by their neurology teams. The sample for the present study was restricted to patients with complete symptom data at baseline.

Ethical approval and procedure {#Sec4}
------------------------------

Ethical approval was obtained from the National Research Ethics Service Committee London South East (REC number: 14/LO/1765). All methods were performed in accordance with the relevant guidelines and regulations. After referral to the OPTCARE Neuro trial and the provision of a patient information leaflet, research nurses visited patients in their homes to obtain written informed consent and collect baseline data, using the Integrated Palliative Outcome Scale Neuro S-24 (IPOS Neuro S-24). Baseline data from the OPTCARE Neuro trial were used for this analysis.

Measures {#Sec5}
--------

### IPOS Neuro S-24 {#Sec6}

The family of Palliative Outcome Scales (POS) measures the palliative care needs of patients^[@CR12]^. The IPOS Neuro-S24 was developed to assess symptoms in LTNC patients. It includes 24 symptom specific items, scored on a 5-point Likert scale from 0 (not at all) to 4 (overwhelmingly), where patients responded how they had been affected by that symptom in the last 3 days^[@CR4]^. Symptoms included in the scale had previously been measured in MS, IPD, PSP and MSA patients^[@CR13]^ and eight core symptoms showed promising psychometric properties following validation in MS, IPD, MSA and PSP patients (forming the IPOS Neuro-S8)^[@CR11]^.

Data analysis {#Sec7}
-------------

Descriptive analyses were used to describe item specific scores, using the mean and standard deviation. Frequency distributions for item-level responses scoring 0 (no problem) to 4 (overwhelmingly) were expressed as frequency and percentage. Floor and ceiling effects were measured by the number of respondents receiving the minimum (0) and maximum (4) score on the individual items. Floor and ceiling effects were deemed present when more than 15% of patients reported the extreme scores^[@CR11]^. The internal consistency (an indicator of reliability) of the measure was calculated using Cronbach's alpha coefficient. Differential Item Functioning (DIF) was used to identify differences (in individual item scores) between MS and IPD patients.

Exploratory factor analysis (EFA) was used to initially evaluate dimensions of the measure. As items were ordered categorical, polychoric correlation was used. EFA using principal factors extraction with oblique rotation was performed. A scree plot and minimum Eigen value of 1.0 were used to identify the number of factors to retain; a minimum factor loading of 0.3 was also specified.

The EFA output was used to inform the confirmatory factor analysis (CFA). The CFA model fit was assessed using fit indices (RMSEA, SRMR, CFI and TLI). The following thresholds were used to indicate a good fitting model: RMSEA \< 0.05, CFI \> 0.95, TLI \> 0.95 and SRMR \< 0.08^[@CR14],[@CR15]^. The modification indices command (*estat mindices*) was used to identify any further factor loadings or covarying error terms that would improve model fit; these were then added to the model. Correlation coefficients were used to assess correlation of factors. Parameters described by Evans *et al*.^[@CR16]^ were used to classify weak (\<0.4), moderate (0.4--0.59) and strong (\>0.6) correlations. Stata 14 was used to perform data analysis.

Results {#Sec8}
=======

Sample characteristics {#Sec9}
----------------------

Data were collected from 350 patients; 284 had complete data for all 24 symptoms. Patients with incomplete symptom data (N = 66) were excluded. Patients lacking mental capacity (N = 39) were missing data as their data were collected via a carer and only patient-reported data were used in analysis, thus these data were missing at random (MAR). The remaining 17 patients with incomplete symptom data were missing data completely at random (MCAR). A further one patient was excluded as their diagnosis ('other') did not meet inclusion criteria. The analytical sample was 283. The descriptive statistics for the 67 excluded patients were comparable to the analytical sample: mean age = 67 years, 51% female, median years since diagnosis = 13, the majority were married, living with spouse, primary/secondary school educated and of white ethnicity. The characteristics of the analytical sample are presented in Table [1](#Tab1){ref-type="table"}.Table 1Sample characteristics (N = 283).AgeMean (SD)66.6 (11.5)Gender% Woman48.4%Diagnosis, N (%)Multiple sclerosis119 (42.1)Idiopathic Parkinson's disease113 (39.9)Multiple system atrophy9 (3.2)Progressive supranuclear palsy20 (7.1)Motor neurone disease22 (7.8)Duration of illness since diagnosis up to enrolment (in years)Mean (SD)12.9 (10.8)*Missing, N*1Marital status, N (%)Single27 (9.5)Widowed32 (11.3)Married/civil partner188 (66.4)Divorced/separated35 (12.4)*Missing, N*1Living arrangement, N (%)Alone54 (19.1)With children19 (6.7)With spouse/partner146 (51.6)With spouse/partner and children35 (12.4)With friend(s)3 (1.1)Other26 (9.2)Educational attainmentPrimary/lower secondary school106 (37.6)Upper secondary school/vocational training100 (35.5)Tertiary76 (27.0)*Missing, N*1EthnicityWhite263 (92.9)Black/African/Caribbean/black British6 (2.1)Other ethnic group13 (4.6)Prefer not to say1 (0.4)

Descriptive statistics and psychometric properties {#Sec10}
--------------------------------------------------

The mean total score of the IPOS Neuro-S24 was 27.0 (SD = 10.3; Range 3--59) (possible range: 0--96). Kurtosis was 3.2 and skewness was 0.5, indicating near normal distribution, which was confirmed by visual inspection of a histogram. The highest scoring items were poor mobility, fatigue and problems using legs (see Table [2](#Tab2){ref-type="table"}). The distributions of each item varied (following visual inspection of histograms for each item), some were normally distributed (feeling sleepy, fatigue, pain), whereas others were positively skewed (shortness of breath, problems using arms, dribbling saliva, amongst others). There was evidence for floor effects for all items except poor mobility, fatigue and problems using legs. Ceiling effects were seen only for poor mobility and problems using legs. The Cronbach's alpha for the sample was 0.77, indicating good internal consistency.Table 2Frequency distribution of symptom scores.SymptomMean (SD)0 (*not at all*) % (n)1 (*slightly*) % (n)2 (*moderately*) % (n)3 (*severely*) % (n)4 (*over-whelmingly*) % (n)Pain1.6 (1.2)23.7 (67)21.2 (60)30.4 (86)21.6 (61)3.2 (9)Shortness of breath0.8 (1.0)50.5 (143)25.1 (71)18.7 (53)4.2 (12)1.4 (4)Nausea0.3 (0.7)78.8 (223)12.4 (35)7.4 (21)0.7 (2)0.7 (2)Vomiting\<0.1 (0.4)97.2 (275)1.4 (4)0.7 (2)---0.7 (2)Poor appetite0.5 (1.0)70.3 (199)12.4 (35)11.7 (33)3.9 (11)1.8 (5)Constipation1.2 (1.2)37.1 (105)19.1 (54)28.3 (80)13.1 (37)2.5 (7)Sore/dry mouth1.0 (1.1)47.0 (133)17.0 (48)25.1 (71)8.5 (24)2.5 (7)Drowsiness1.5 (1.1)25.8 (73)19.4 (55)38.5 (109)13.1 (37)3.2 (9)Poor mobility2.8 (1.0)3.9 (11)6.7 (19)22.3 (63)41.7 (118)25.4 (72)Spasms1.2 (1.2)39.9 (113)20.9 (59)20.9 (59)13.1 (37)5.3 (15)Fatigue2.1 (1.1)10.3 (29)17.3 (49)37.1 (105)26.2 (74)9.2 (26)Problems swallowing0.7 (1.0)60.1 (170)15.9 (45)16.3 (46)6.4 (18)1.4 (4)Feeling sleepy1.8 (1.1)16.6 (47)20.5 (58)35.0 (99)21.6 (61)6.4 (18)Difficulty sleeping1.1 (1.2)48.4 (137)14.1 (40)22.6 (64)12.0 (34)2.8 (8)Difficulty controlling bowels0.9 (1.2)54.1 (153)21.2 (60)12.4 (35)7.1 (20)5.3 (15)Difficulty controlling urine1.4 (1.3)37.5 (106)20.5 (58)19.4 (55)14.1 (40)8.5 (24)Pressure sores0.3 (0.7)84.5 (239)7.0 (20)5.3 (15)2.5 (7)0.7 (2)Problems using arms1.4 (1.2)32.5 (92)21.9 (62)23.3 (66)17.0 (48)5.3 (15)Problems using legs2.6 (1.2)8.8 (25)9.2 (26)19.1 (54)39.6 (112)23.3 (66)Difficulty communicating1.1 (1.1)42.4 (120)23.0 (65)21.6 (61)11.3 (32)1.8 (5)Dribbling saliva0.9 (1.1)49.8 (141)23.7 (67)13.8 (39)10.3 (29)2.5 (7)Falls0.8 (1.1)60.4 (171)16.6 (47)13.1 (37)7.1 (20)2.8 (8)Hallucinations0.4 (0.8)75.6 (214)13.1 (37)7.4 (21)2.8 (8)1.1 (3)Mouth problems0.6 (1.0)69.3 (196)13.4 (38)10.3 (29)5.3 (15)1.8 (5)

Differential Item Functioning {#Sec11}
-----------------------------

Symptom scores were compared in MS and IPD patients (as the two biggest patient groups in this sample) using differential item functioning (DIF) analysis (results presented in [Supplementary Material](#MOESM1){ref-type="media"}). Using a sub-sample of 196 MS (N = 119) and IPD (N = 113) patients, DIF was found for nine of the 24 items: patients with MS were more likely to report poor appetite, spasms, difficultly controlling bowels, problems using arms and problems using legs and patients with IPD were more likely to report difficulty communicating, dribbling saliva, hallucinations and mouth problems.

Factor analysis {#Sec12}
---------------

The EFA retained eight factors after specifying a minimum eigen value of 1.0. However, less than 3 items loaded onto factors 5, 6, 7 and 8 (with factor loadings \> 0.3), thus four factors were retained in the CFA. Falls was the only item to not load onto a factor and was excluded from the model.

Covarying error terms were added for the following items: drowsiness and feeling sleepy, poor mobility and problems using legs, sore/dry mouth and difficultly communicating, sore/dry mouth and dribbling saliva, sore/dry mouth and mouth problems, nausea and vomiting. The final model is shown in Table [3](#Tab3){ref-type="table"}.Table 3Confirmatory factor analysis; Standardised factor loadings (Standard error).Factor One -Fatigue related symptomsFactor Two -Motor related symptomsFactor Three -Oral problemsFactor Four -Non-motor symptomsDrowsiness0.50 (0.06)Fatigue0.84 (0.05)Feeling sleepy0.63 (0.05)Difficulty controlling urine0.30 (0.06)Constipation0.30 (0.07)Poor mobility0.59 (0.06)Spasms0.50 (0.06)Difficulty controlling bowels0.42 (0.06)Pressure sores0.34 (0.07)Problems using arms0.59 (0.06)Problems using legs0.60 (0.06)Sore/dry mouth0.61 (0.08)Problems swallowing0.56 (0.06)Difficulty communicating0.62 (0.06)Dribbling saliva0.59 (0.06)Hallucinations0.30 (0.06)Mouth problems0.46 (0.06)Pain0.51 (0.06)Shortness of breath0.33 (0.07)Nausea0.51 (0.06)Poor appetite0.48 (0.06)Vomiting0.37 (0.07)Difficulty sleeping0.44 (0.06)FallsFit statistics^a^AIC = 17845.017, RMSEA = 0.045, CFI = 0.894, TLI = 0.876, SRMR = 0.064^a^AIC -- Akaike information criterion.RMSEA -- Root mean square error of approximation.CFI -- Confirmatory fit index.TLI -- Tucker-Lewis Index.SRMR -- Standardised root mean squared residual.

The CFA produced a fairly good-fitting model, as indicated by the goodness of fit statistics (RMSEA = 0.045 and SRMR = 0.064 both indicated a good fit, the CFI (0.894) and TLI (0.876) are approaching adequate fit). Moreover, this model was robust when repeated for MS and IPD patients independently (see Supplementary Material).

Factors were mostly weakly to moderately correlated. Fatigue related symptoms were moderately correlated with motor related symptoms (0.45) and strongly correlated with non-motor symptoms (0.62). Non-motor symptoms were moderately correlated with motor related symptoms (0.44) and oral problems (0.40). Oral problems were weakly correlated with fatigue related symptoms (0.23) and motor related symptoms (0.06).

Discussion {#Sec13}
==========

This is the first assessment of a range of symptoms across LTNCs using factor analysis, utilising baseline data from a multicentre clinical trial. The IPOS Neuro-S24 is a promising measure of symptoms across LTNCs and data using this measure produced a clinically meaningful four-factor model illustrating symptom dimensions related to fatigue, motor symptoms, oral problems and non-motor symptoms.

The first factor predominantly included fatigue related symptoms. The factor loadings were generally high for these symptoms. Similar results were reported in a cluster analysis of symptoms in cancer patients^[@CR17]^, as fatigue, lack of energy and weakness clustered together. Although the statistical techniques differed, it could be concluded that across these patient groups, these symptoms tend to appear together.

The second factor represented symptoms relating to motor control and mobility. Although difficulty controlling bowels appears to be less similar to the other symptoms that load on to this factor, bowel problems may be a symptom of LTNCs due to nerve damage or loss of muscle control. Similarly, constipation can result from lack of physical activity. Problems relating to mobility frequently appear in the literature exploring symptomatology in LTNCs. In a systematic review of LTNC symptoms^[@CR4]^, in 40 articles there were 18 different descriptors of mobility symptoms/problems and these symptoms were highly prevalent (\>80% patients). The present study adds to this as the results demonstrate that symptoms presenting as the adverse effects of poor mobility (eg, pressure sores, constipation) load onto the same factor.

The third factor predominantly represented oral problems. Oral symptoms (including communication, swallowing and dribbling/drooling) were presented by Saleem *et al*.^[@CR4]^ as commonly reported symptoms in the LTNC literature. The present study adds to this by suggesting that these symptoms often co-occur.

The last factor included non-motor symptoms. It also included gastro-intestinal symptoms. These results are supported by Fink *et al*.^[@CR18]^, who found a gastro-intestinal factor in their analysis of symptoms in patients from a neurology clinic, general medicine and primary care.

Although most symptoms that load onto factors fit within a logical 'theme', there were seemingly miscellaneous symptoms, particularly difficulty controlling urine and hallucinations. Difficulty controlling urine loaded onto fatigue related symptoms, however this could be related to nocturia, muscle weakness and/or toileting problems due to poor mobility or lack of energy. Hallucinations, a neuropsychiatric non-motor symptom typically seen in IPD patients^[@CR19]^, loaded onto oral problems. Swallowing dysfunction in IPD relates to more widespread Lewy bodies, or dry mouth due to anti-cholinergics may be a risk factor for confusion. Additionally, it is worth noting that many symptoms reported by patients may be related to treatments rather than the condition itself^[@CR3]^. Thus, although factor analysis demonstrates where symptoms load onto common factors, it does not account for when one symptom might be caused by another, or may be symptomatic of a treatment for another symptom.

A key finding was the robustness of the factor model (and symptom dimensions) across different LTNCs. DIF was found for nine of the 24 items. However, it is worth noting that the Mantel-Haenszel tests used produced wide confidence intervals for spasms, problems using legs and hallucinations and mouth problems was borderline significant, indicating weak evidence for DIF. The CFA model fit the data (although to slightly less a degree) for MS and IPD patients independently. The models were comparable, however the fit statistics indicated the model fit the data best when using the whole sample, suggesting that the model was appropriate for use across LTNCs.

As this factor analysis was the first of its kind using a large number of motor and non-motor symptoms in this patient group, it is difficult to compare with other established measures. A factor analysis including patients with LTNCs using eight of the symptoms also used in the present study (pain, shortness of breath, nausea, vomiting, constipation, spasms, difficulty sleeping and mouth problems) reported a similar Cronbach's alpha (0.66), also indicating good internal consistency^[@CR11]^. As this scale comprised fewer items than the IPOS Neuro S-24, it presented fewer factors (two), which were not able to represent multiple symptom groups. It did, however, present good fit indices (SRMR = 0.057, RMSEA = 0.046), comparable to those seen in the present study. Two symptom measures identified in the literature^[@CR17],[@CR18]^, each comprising 25 symptoms, though not using LTNC samples, demonstrated how symptoms were likely to co-occur in different patient groups. In a factor analysis of symptoms in both neurological and general medical patients, three factors were observed: cardiopulmonary, musculoskeletal and gastrointestinal symptoms. In a cluster analysis of symptoms in patients with cancer, seven symptom clusters were identified. These findings suggest that including a wider range of symptoms in a measure has the benefit of demonstrating if and which symptoms are likely to co-occur by indicating a number of symptom groups.

These results have implications for care and research in LTNCs. This study demonstrates that symptom dimensions are similar across LTNCs and that a single tool can be used to measure the outcome in this patient group. Moreover, the results may benefit clinical practice as symptom factors indicate that, where an individual reports experiencing one symptom, they are more likely to experience other symptoms that load on to the same factor. Better understanding of symptoms in LTNCs is necessary for the care of patients^[@CR3]--[@CR5]^, particularly palliative care, which is focused on symptom management and comfort. Previous research has found that collaborative working between neurology and palliative care professionals has room for improvement^[@CR20]^; a palliative outcome measure specifically for patients with LTNCs could influence these working practices and patient outcomes in future.

This study benefitted from a relatively large clinical sample (N = 283) given that recruitment of palliative patients is difficult and numbers of LTNC patients are smaller compared to other incurable conditions. Potential limitations of the present study include exclusion of patients lacking capacity, as only patient-reported ratings were included in the factor analysis, and exclusion of patients with missing data. The IPOS Neuro-S24 comprises predominantly physical symptoms, rather than psychiatric, behavioural or cognitive symptoms. However, this was the nature of the measure, thus exploration of psychiatric, behavioural or cognitive symptoms was beyond the scope of this study.

The results from this study produced a reliable four-factor CFA model, using baseline data from a clinical sample of LTNC patients. Four stable symptom domains were identified: fatigue related symptoms, motor/mobility related symptoms, oral problems and gastric/other symptoms. Although floor effects were present, the IPOS Neuro S-24 showed promising psychometric properties and is an appropriate tool to measure symptoms in this patient group. This will enable health care providers to assess and monitor symptomatology in this patient group and provide appropriate and integrated neurological and palliative care.
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